Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BLACANDI

Financiado

Cerrado

BLACANDI can improve life quality and cut cost of diagnosing and managing bladde...

BLACANDI can improve life quality and cut cost of diagnosing and managing bladder cancer in half The BLACANDI project aims to dramatically improve the diagnosis and management of bladder cancer patients by substituting a highly invasive and expensive test with a non-invasive and inexpensive test. Bladder cancer is the 6th mos... ver más

31/12/2015

GENOMIC EXPRESSION...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

GENOMIC EXPRESSION APS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-12-31

PHC-12-2014-1: Clinical research for the validatio...

I+D

Cerrada hace 10 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GENOMIC EXPRESSION APS

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

LAUREN bLadder cAncer URine cEll aNalysis 3M€ Cerrado

OneRNA4Bladder Non invasive Cell Based Liquid Biopsy Platform for Bladder C... 4M€ Cerrado

PROSTATOR Reliable urinary test for the diagnosis of prostate cancer 150K€ Cerrado

BlaC E-assay Portable electrochemical assay system for on chip quantitati... 195K€ Cerrado

PTQ-10-03892 PROYECTO BLADDERMATRIXINVESTIGACIÓN, DESARROLLO Y VALIDACIÓN... 120K€ Cerrado

RNADIAGON Excellence in research and development of non coding RNA DIA... 662K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2015-06-10
Fecha Fin: 2015-12-31

Líder del proyecto

GENOMIC EXPRESSION APS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The BLACANDI project aims to dramatically improve the diagnosis and management of bladder cancer patients by substituting a highly invasive and expensive test with a non-invasive and inexpensive test. Bladder cancer is the 6th most common cancer with an estimated 357,000 new cases worldwide every year, of which 180,000 are European. This type of cancer has the highest lifetime treatment costs per patient (pp) of all cancers. This high incidence, coupled with it’s relapsing nature, means that bladder cancer poses an enormous burden on health care systems. Current diagnostics and recurrence routine tests are performed through highly invasive and expensive procedures, such as cystoscopy. The Danish SME Genomic Expression Aps has licensed a technology composed of a patented filtration device that enhances the selection of tumor cells in urine, and aims at the clinical validation of a new combination of biomarkers. Our solution BLACANDI (Filtration Device in combination with selected biomarkers) is currently being tested in a small clinical trial in Denmark, in patients presenting with hematuria (blood in urine). Preliminary results indicate that the test can substitute cystoscopy identifying more than 90% of all bladder cancer patients. Substituting routine cystoscopy with the BLACANDI system could cut the cost of diagnosis and managing bladder cancer in half. In Europe the cost of diagnosing bladder cancer is €1.8 billion/year, thus we could save €900 million. Whereas the technology behind the filtration device and the selected biomarkers is already demonstrated, further maturation of the tests into fully commercial and operational solutions is hampered by the absence of a large clinical validation of the BLACANDI system. Furthermore, there is a need to corroborate our business strategy, since it requires customization to different health care systems. This phase 1 feasibility study provides us that opportunity.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores